LEVETIRACETAM-AFT levetiracetam 100 mg/mL oral solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

levetiracetam-aft levetiracetam 100 mg/ml oral solution bottle

aft pharmaceuticals pty ltd - levetiracetam, quantity: 10 % w/v - oral liquid, solution - excipient ingredients: acesulfame potassium; propyl hydroxybenzoate; purified water; maltitol solution; glycerol; sodium citrate dihydrate; methyl hydroxybenzoate; ammonium glycyrrhizinate; citric acid monohydrate; flavour - levetiracetam-aft oral solution is indicated for:,use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam-aft concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

KEPPRA levetiracetam 100 mg/mL oral solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

keppra levetiracetam 100 mg/ml oral solution bottle

ucb australia pty ltd t/a ucb pharma division of ucb australia - levetiracetam, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: acesulfame potassium; purified water; maltitol solution; methyl hydroxybenzoate; ammonium glycyrrhizinate; citric acid monohydrate; propyl hydroxybenzoate; sodium citrate dihydrate; glycerol; flavour - keppra (film coated tablets and oral solution) is indicated for - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation, - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. - add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and - add on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige). keppra concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

BRIVIACT brivaracetam 10mg/mL oral solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

briviact brivaracetam 10mg/ml oral solution bottle

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate dihydrate; purified water; methyl hydroxybenzoate; citric acid; glycerol; carmellose sodium; sorbitol solution (70 per cent) (crystallising); sucralose; flavour - briviact oral solution is indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

VIMPAT lacosamide 10 mg/mL oral solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

vimpat lacosamide 10 mg/ml oral solution bottle

ucb australia pty ltd t/a ucb pharma division of ucb australia - lacosamide, quantity: 10 mg - solution - excipient ingredients: glycerol; sodium chloride; carmellose sodium; sorbitol solution (70 per cent) (crystallising); macrogol 4000; citric acid; acesulfame potassium; sodium methyl hydroxybenzoate; purified water; flavour - vimpat (lacosamide) tablets and oral solution are indicated as:,? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.,? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older.,? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

ZIAGEN abacavir (as sulfate) 20mg/mL oral solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

ziagen abacavir (as sulfate) 20mg/ml oral solution bottle

viiv healthcare pty ltd - abacavir sulfate, quantity: 23.4 mg/ml (equivalent: abacavir, qty 20 mg/ml) - oral liquid, solution - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); sorbitol solution (70 per cent) (crystallising); propylene glycol; sodium citrate dihydrate; citric acid; methyl hydroxybenzoate; propyl hydroxybenzoate; saccharin sodium; hydrochloric acid; sodium hydroxide; purified water; flavour - ziagen (abacavir) is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and children (see clinical trials). this indication is based on surrogate endpoints in studies up to 48 weeks in duration.

Night Nurse oral solution United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

night nurse oral solution

haleon uk ltd - paracetamol; promethazine hydrochloride; dextromethorphan hydrobromide - oral solution - 50mg/1ml ; 1mg/1ml ; 750microgram/1ml

Night Nurse oral solution United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

night nurse oral solution

de pharmaceuticals - paracetamol; promethazine hydrochloride; dextromethorphan hydrobromide - oral solution - 50mg/1ml ; 1mg/1ml ; 750microgram/1ml

Fedril Night Cold and Flu oral solution United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

fedril night cold and flu oral solution

pinewood healthcare - paracetamol; promethazine hydrochloride; dextromethorphan hydrobromide - oral solution - 50mg/1ml ; 1mg/1ml ; 750microgram/1ml

Neoral 100mg/ml oral solution United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

neoral 100mg/ml oral solution

novartis pharmaceuticals uk ltd - ciclosporin - oral solution - 100mg/1ml

KERRON levetiracetam 100 mg/mL oral solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

kerron levetiracetam 100 mg/ml oral solution bottle

strides pharma science pty ltd - levetiracetam, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: maltitol solution; purified water; citric acid monohydrate; glycerol; methyl hydroxybenzoate; propylene glycol; sodium citrate dihydrate; acesulfame potassium; propyl hydroxybenzoate; ammonium glycyrrhizinate; flavour - use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation; monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).